Spots Global Cancer Trial Database for Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC
Official Title: Fraction Dose Escalation of Hypofractionated Radiotherapy With Concurrent Chemotherapy and Subsequent Consolidation Immunotherapy in Locally Advanced Non-small Cell Lung Cancer: a Phase 1 Study
Study ID: NCT04951063
Conditions
Study Description
Brief Summary: This Phase 1 trial aimed to determine the maximum tolerated fraction dose (MTD) of hypofractionated radiotherapy (hypo-RT) combined with concurrent chemotherapy and subsequent consolidation immune checkpoint inhibitors (cICI) for patients with locally advanced non-small cell lung cancer (LA-NSCLC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact Details
Name: Hui Liu, Professor
Affiliation: Sun yat-sen universtiy cancer center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
